Objective. To explore the clinical efficacy and safety of apatinib combined with paclitaxel in the first-line treatment of locally advanced nasopharyngeal carcinoma. Methods. From March 2016 to June 2018, 114 patients with locally advanced nasopharyngeal carcinoma who received first-line treatment in our hospital were selected as the patient group, and those who received apatinib combined with paclitaxel concurrent radiotherapy and chemotherapy were selected as the research group (n = 54), while those who received paclitaxel concurrent radiotherapy and chemotherapy were selected as the control group (n = 60). Sixty healthy individuals in our hospital were recruited in the same period as the healthy group. The clinical effective rate, adverse reactions, 2-year overall survival rate (OS), 2-year progression-free survival rate (PFS), and quality of life were compared between the two groups, and the expression of miR-655 in the serum of each group was tested by RT-qPCR. Results. The total clinical effective rate of the research group was higher than that of the control group, and the 2-year OS and PFS of the research group were also higher than those of the control group (). Both groups of patients could tolerate the treatment, but the incidence of hypertension and proteinuria in the research group was higher than that in the control group (). The expression of miR-655 in the serum of patients was lower than that of the healthy group (). After treatment, miR-655 in serum increased in both the groups and miR-655 in the research group was higher than that in the control group (). The 2-year survival rate of OS and PFS in patients with low expression of miR-655 was significantly lower than that in patients with high expression of miR-655 (). Conclusion. Apatinib combined with paclitaxel concurrent radiotherapy and chemotherapy is effective and well-tolerated in the treatment of locally advanced nasopharyngeal carcinoma, which improves the quality of life of patients and can be popularized in clinical practice. In addition, the increase of miR-655 may be a target for treating nasopharyngeal carcinoma.

中文翻译：

---

甲磺酸阿帕替尼片联合紫杉醇放化疗一线治疗局部晚期鼻咽癌的临床疗效

客观。探讨阿帕替尼联合紫杉醇一线治疗局部晚期鼻咽癌的临床疗效和安全性。方法。选择2016年3月至2018年6月在我院接受一线治疗的114例局部晚期鼻咽癌患者作为患者组，选择接受阿帕替尼联合紫杉醇同步放化疗的患者作为研究组（n  = 54），同时选择接受紫杉醇同步放化疗者作为对照组（n = 60)。与健康组同期招募我院健康人60人。比较两组临床有效率、不良反应、2年总生存率（OS）、2年无进展生存率（PFS）和生活质量，以及miR-655在各组血清采用 RT-qPCR 检测。结果。研究组临床总有效率高于对照组，研究组2年OS和PFS也高于对照组（）。两组患者均能耐受治疗，但研究组高血压、蛋白尿发生率高于对照组（）。患者血清中miR-655的表达低于健康组（）。治疗后，两组血清中miR-655均升高，研究组miR-655高于对照组（）。miR-655低表达患者的OS和PFS 2年生存率显着低于miR-655高表达患者。）。 结论。阿帕替尼联合紫杉醇同步放化疗治疗局部晚期鼻咽癌疗效好、耐受性好，提高了患者的生活质量，可在临床上推广。此外，miR-655的增加可能是治疗鼻咽癌的靶点。